Mitochondrial dysfunction and potential anticancer therapy
Matilde E. Lleonart, Robert Grodzicki, Dmitri M. Graifer, Alex Lyakhovich
Index: 10.1002/med.21459
Full Text: HTML
Abstract
Mitochondrial dysfunction (MDF) has been identified as an important factor in various diseases ranging from neurological disorders, to diseases of the cardiovascular system and metabolic syndromes. MDF was also found in cancer as well as in cancer predisposition syndromes with defective DNA damage response (DDR) machinery. Moreover, a recent highlight arises from the detection of MDF in eukaryotic cells upon treatment with antibiotics. In this review, we focus on recent studies of MDF in pathological conditions with a particular emphasis on the effects of various classes of antibiotics on mitochondria. Special attention is given to the role of autophagy/mitophagy in MDF and repurposing antibiotics as anticancer drugs.
Latest Articles:
2017-07-11
[10.1002/med.21458]
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy
2017-07-06
[10.1002/med.21456]
2017-07-03
[10.1002/med.21457]
Tumor angiogenesis revisited: Regulators and clinical implications
2017-06-23
[10.1002/med.21452]
Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action
2017-06-23
[10.1002/med.21446]